Related references
Note: Only part of the references are listed.Deep vein thrombosis in pediatric patients
Julie Jaffray et al.
PEDIATRIC BLOOD & CANCER (2018)
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab
Yesim Dargaud et al.
HAEMATOLOGICA (2018)
Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab
K. Nogami et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Hemostasis in the Very Young
Gili Kenet et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2018)
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab
Yesim Dargaud et al.
HAEMATOLOGICA (2018)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Peter J. Lenting et al.
BLOOD (2017)
Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors
Tami Livnat et al.
BLOOD CELLS MOLECULES AND DISEASES (2017)
Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project
Marilyn J. Manco-Johnson et al.
BLOOD (2017)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Midori Shima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors
Cindy A. Leissinger et al.
BLOOD (2015)
Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland
K. Vepsalainen et al.
HAEMOPHILIA (2015)
Toward optimal therapy for inhibitors in hemophilia
Christine L. Kempton et al.
BLOOD (2014)
Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy
F. Abbonizio et al.
HAEMOPHILIA (2014)
Port-A-Cath infection causes inhibitor recurrence after initial successful ITI
G. Grangl et al.
HAEMOPHILIA (2013)
Validating the Difficult Intravenous Access Clinical Prediction Rule
Michael Brendan O'Neill et al.
PEDIATRIC EMERGENCY CARE (2012)
Venous access in haemophilic children: choice and management
E. SANTAGOSTINO et al.
HAEMOPHILIA (2010)
Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance
V. Terraube et al.
HAEMOPHILIA (2010)
Optimizing outcomes for patients with severe haemophilia A
S. W. Pipe et al.
HAEMOPHILIA (2007)
Calibrated automated thrombin generation measurement in clotting plasma
HC Hemker et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2003)
Share Paper
